• NAVC Brands

Cytauxzoonosis in Cats

Because cytauxzoonosis in cats is associated with a high mortality rate and costly treatment, tick prevention is critical.

Christina PacholecDVM

Dr. Pacholec obtained her DVM degree at Kansas State University and then completed a rotating internship at Auburn University College of Veterinary Medicine, followed by an Internal Medicine residency at the University of Missouri. In alignment with her emerging clinical interest, she started a combined Clinical Pathology residency and PhD program at Virginia Tech in the summer of 2020. Her clinical and research interests include immune-mediated diseases, pharmacology, infectious diseases, and clinical pathology.


Dr. Cohn is a Professor of Veterinary Medicine and Surgery at the University of Missouri College of Veterinary Medicine. Her clinical and research interests include respiratory and infectious diseases of dogs and cats. She has a special interest in vector-borne diseases, and a long-standing goal is to help prevent or improve the clinical outcome of cats afflicted with cytauxzoonosis. She is the co–editor-in-chief of the textbook Côté’s Clinical Veterinary Advisor, 4th edition.

Cytauxzoonosis in Cats

Cytauxzoonosis, caused by the hematoprotozoan pathogen Cytauxzoon felis, is a devastating illness of domestic cats. However, although cytauxzoonosis in cats was once thought to be uniformly fatal, we now recognize that domestic cats can survive infection and serve as reservoirs for pathogen spread via the tick vectors, as occurs with the wild felid reservoir hosts. Nonetheless, infection of domestic cats most often leads to an acute illness that is costly to treat and associated with a high mortality rate.


Much of the C. felis life cycle is inferred from what we know of related Piroplasmidae such as Theileria. Experimental studies are made more difficult because, thus far, the pathogen has not been cultured in vitro. C. felis infection of the wild felid reservoir hosts (e.g., bobcats) typically causes mild to moderate illness with a low mortality rate.1 Reservoir hosts maintain chronic erythroparasitemia that permits transmission of the pathogen to tick vectors. Survivors remain infected with C. felis but no longer have cytauxzoonosis (TABLE 1).

In the United States, the predominant tick vector is the lone star tick, Amblyomma americanum, but other ticks might also transmit infection.2 While feeding on an infected reservoir host, the naive tick ingests organisms that then undergo sexual reproduction in the tick (FIGURE 1). The parasite persists in the tick as it transitions from one life stage to the next (transstadial transmission). During the tick’s next blood meal, C. felis zygotes move into the tick’s salivary glands, where they mature into infective sporozoites. In as few as 36 hours after the tick next feeds on a naive host, sporozoites enter the host’s mononuclear cells, where they undergo schizogony, a form of asexual reproduction.4 Schizont-laden mononuclear cells are characteristic of the acute disease phase of infection (i.e., cytauxzoonosis).

If the infected cat survives long enough, merozoites are released from ruptured macrophages and are taken up by red blood cells (RBCs), where they can be visualized as piroplasms. At the time of disease diagnosis, most cats have both identifiable tissue schizonts and RBC piroplasms. In surviving cats (wild or, less commonly, domestic), asexual reproduction comes to a halt in the mononuclear cells but continues in the RBCs. For months to years, carrier cats maintain a low-level parasitemia, which facilitates parasite transmission to feeding ticks.

Of note, no evidence of naturally occurring cat-to-cat transmission in the absence of a tick vector has been found. Although perinatal transmission of closely related Theileria and Babesia species is well documented, perinatal transmission of C. felis has not been demonstrated.5 Ingestion of infected ticks does not result in cytauxzoonosis.4 Transfusion of blood from recovered cats permits erythroparasitemia but does not result in clinical illness.6 Experimentally, disease can be caused by parenteral administration of schizont-laden mononuclear cells from tissues (i.e., spleen) or blood collected from cats during the period of clinical illness.7


First recognized in Missouri in 1976, cytauxzoonosis was believed to be limited to the south-central United States for many years thereafter.8 More recently, it has dramatically expanded geographically within the United States, and the same or similar organisms have been recognized in South America, Europe, and Asia. Expansion in the United States probably corresponds to an expanding territory for the lone star tick vector. The disease has now been recognized in most states in the south-central, southeastern, and mid-Atlantic United States (FIGURE 2).9,10 In most of the United States, survival of untreated domestic cats is rare; however, there are geographic pockets (e.g., northwestern Arkansas) where disease in domestic cats can be mild or inapparent.11,12 The cause for virulence differences in various geographic regions remains unexplained.

The incidence and prevalence of C. felis depend on geographic location. Because cytauxzoonosis is not reportable, and many cats probably die without having received veterinary care, estimating disease incidence is extremely difficult. The authors have personal knowledge of rural and suburban private veterinary practices in cytauxzoonosis-endemic regions that diagnose cytauxzoonosis in 20 to 40 cats each summer, while practices only 100 miles away rarely make that diagnosis. Cytauxzoonosis was the reason for 1.5% of all cat admissions to the Boren Veterinary Medical Teaching Hospital at Oklahoma State University from 1998 through 2006.13 Prevalence would be low in areas where incidence of infection is low or if most infected cats quickly succumb. Prevalence among apparently healthy domestic cats from C. felis-endemic regions has been reported to range from zero to 15.5%; prevalence was higher in the region of Arkansas reported to have less virulent disease.12,14,15 Among wild cats, the reported prevalence in endemic regions is up to 79%.10

History and Physical Examination for Cytauxzoonosis

Clinical signs of cytauxzoonosis usually become apparent 8 to 12 days after infection.2 Macrophages become distended with schizonts, leading to variable degrees of vessel occlusion in the liver, spleen, pulmonary parenchyma, and central nervous system.
As schizonts rupture, the liberated merozoites enter RBCs, leading to immune-mediated destruction of the infected cells and subsequent anemia. Although no history or examination finding is pathognomonic for cytauxzoonosis, there are typical characteristic features.

Cats of any age, breed, or sex can be infected, but most commonly affected are active adult cats that spend time outdoors in endemic rural or semirural areas.13 In most areas, disease incidence peaks in early spring, continues throughout the summer, and peaks again (smaller peak) in early autumn.13 Although infection is more likely in cats not receiving ectoparasite prophylaxis, inappropriate choice of product or mistakes in application might allow for infection despite the client’s reported use of ectoparasite control. Often, clients will note that their previously healthy cat suddenly demonstrates reduced appetite, followed rapidly by anorexia, lethargy, and sometimes vocalization, interpreted as pain or discomfort.

The most consistent abnormality detected by physical examination of an acutely infected cat is pronounced fever.7,16,17 Although a large majority of infected cats are febrile at presentation, hypothermia can occur late in the course of disease and is a very poor prognostic sign. Other findings may include icterus, pallor, and organomegaly (TABLE 2). The entire disease course progresses rapidly, and death within 36 hours of presentation for veterinary care is common.

Diagnostic Testing for Cytauxzoonosis

Confirmation of cytauxzoonosis depends on identification of the parasite microscopically or via molecular methods in combination with typical clinical findings. A number of other diagnostic tests might be indicated to help identify comorbid conditions or disease complications that may require intervention. For example, tachypnea and respiratory distress are not uncommon complications, resulting from either pulmonary vascular obstruction with schizont-distended cells or from pleural fluid accumulation. When respiratory signs are present, thoracic radiographs or thoracic ultrasonography may be helpful. Abdominal imaging often confirms organomegaly but seldom alters therapy.

Although cytauxzoonosis results in a number of abnormalities commonly recognized on routine blood and urine tests (TABLE 3), the only specific finding is the pathogen.7,16,17 Serum biochemical findings often include hyperbilirubinemia, hyperglycemia, and hypoproteinemia; occasionally, electrolyte derangements such as hypokalemia require intervention. Coagulation tests often reflect disseminated intravascular coagulation (DIC).18 Anemia may not be present initially, but as merozoites invade RBCs, hemolysis results and might warrant transfusion. Pancytopenia is common, and lymphocytes sometimes appear large and granular.

The most useful diagnostic method is identification of organisms on Wright- or Wright-Giemsa–stained blood smears, but this method is not perfectly sensitive or specific. Intraerythrocytic merozoites (i.e., piroplasms) most commonly appear as signet ring-shaped inclusions 1 to 2 µm in diameter but may appear as tetrads, bipolar oval structures, or round anaplasmoid bodies ranging from 0.2 to 2.5 µm (FIGURE 3). The organisms are indistinguishable from Babesia felis, a pathogen not yet identified in the United States. Although piroplasms are often numerous during clinical disease (up to 50% of RBCs may contain parasites), they may be absent at the onset of clinical signs. In these very early infections, piroplasms can become apparent on re-examination of a new blood smear even just 12 hours later. Note that occasional piroplasms remain identifiable in recovered carrier cats;11,19 thus, identification of piroplasms can demonstrate infection but does not confirm acute disease (i.e., cytauxzoonosis) in the absence of compatible clinical signs. Rarely, schizont-laden mononuclear cells (FIGURE 4) are seen on a peripheral blood smear. Unlike piroplasms, visualization of these cells is confirmatory for the disease because schizonts are not present in chronically infected carriers.20 Although identifying schizonts on a blood smear is rare, identification of schizonts in tissues is both common and diagnostic for cytauxzoonosis. Fine-needle aspirates from spleen, lymph nodes, liver, or lungs might demonstrate schizonts before piroplasms are found on a blood smear, but obtaining aspirates from hypocoagualable patients may lead to hemorrhage. Schizonts are readily identifiable on tissue biopsy samples (rarely performed) or necropsy, making cytauxzoonosis a very straightforward postmortem diagnosis (FIGURE 5).21

Molecular testing for C. felis infection is commercially available and extremely sensitive; in experimentally infected cats, positive results precede clinical disease and recognition of organisms on blood smear by up to several days.22,23 Because polymerase chain reaction (PCR) is so sensitive, results can remain positive in recovered carrier cats.24 Thus, as for piroplasm identification, a positive PCR does not confirm a disease diagnosis in the absence of clinical findings. Serologic testing is not commercially available.

Treatment and Prognosis for Cytauxzoonosis

There is no simple or inexpensive cure for cytauxzoonosis. Over the years, numerous antiprotozoal drugs have been investigated and were largely found to have little efficacy. The current treatment of choice is oral administration of the antimalarial drug atovaquone (Mepron; GlaxoSmithKline, gsk.com) and the antimicrobial drug azithromycin (Zithromax; Pfizer, pfizer.com) combined with supportive care (BOX 1).16 Although without treatment the mortality rate is nearly 100%, with appropriate treatment the rate falls to 40%. Atovaquone works by targeting cytochrome b; treatment failures might be explained by mutations in cytochrome b in some parasites because different parasite cytochrome b genotypes resulted in different treatment outcomes.25 Despite improved survival rates with this combination therapy, the treatment is expensive and difficult to administer. Atovaquone is a viscous liquid; the authors advise that after filling the syringe, its contents be allowed to settle to ensure that the full volume is present. Cats dislike the flavor of the medication, which is given every 8 hours. For this reason, we advise early placement of a nasoesophageal feeding tube to allow for less stressful administration of medication as well as nutritional support. Although no studies have documented the useful aspects of supportive care, in the authors’ opinion, minimizing stress seems to be key to survival. Judicious use of crystalloid fluids and administration of analgesics are probably beneficial. The authors avoid nonsteroidal fever-reducing agents because we have the impression that they lead to a worsened outcome in treated cats; instead, focus is placed on analgesia by using agents such as buprenorphine. Some clinicians advocate the use of anti-inflammatory prednisolone, but there is no evidence that this practice is either beneficial or detrimental. Although the authors have administered heparin for DIC prophylaxis/treatment, no benefit has been documented. Other forms of support may be indicated on a case-by-case basis and include transfusion for anemia, oxygen therapy for pneumonitis, thoracocentesis for pleural effusion, or anticonvulsants for seizures.

BOX 1 Treatment for Cytauxzoonosis

Antiprotozoal therapy

  • Atovaquone 15 mg/kg PO q8h for 10 days
  • Azithromycin 10 mg/kg PO q24h for 10 days

Supportive care for most patients

  • Minimize stress and handling
    • Nasoesophageal/nasogastric feeding tube (for ease of medication and nutritional support administration)
  • Analgesia (e.g., buprenorphine; authors avoid nonsteroidal anti-inflammatory drugs)
  • Judicious use of crystalloid fluids
  • Correction of electrolyte abnormalities
  • +/- Heparin (300 IU/kg SQ q8h)

Supportive care for some patients (should be tailored to individual patient’s needs)

  • Packed RBC or whole blood transfusion
  • Appetite stimulant (e.g., mirtazapine 2 mg/cat transdermally q24h)
  • Antiemetics (e.g., maropitant citrate 1 mg/kg PO or SQ q24h)
  • Oxygen supplementation
  • Therapeutic thoracocentesis
  • Anticonvulsants
  • Fresh or frozen plasma

Chronic carriers of C. felis are not ill and do not require specific therapy. Several treatments have been investigated to determine if the carrier state, and thus the risk of acting as a reservoir host, can be eliminated. Atovaquone and azithromycin dramatically reduced pathogen burden but did not completely eliminate infection.26 Neither diminazene diaceturate nor imidocarb diproprionate has been able to eliminate the pathogen.26,27

Prevention of Cytauxzoonosis

Currently, cytauxzoonosis is best prevented by keeping ticks from feeding on cats. Keeping cats indoors is helpful, but because ticks can come indoors and because indoor cats occasionally escape to the outdoors, tick prevention in cytauxzoonosis-endemic areas is strongly recommended. High efficacy for preventing C. felis infection has been shown by the use of collars containing imidacloprid 10%/flumethrin 4.5% (Seresto; Bayer, animalhealth.bayer.com) or topical application of selamectin plus sarolaner (Revolution Plus; Zoetis, zoetis.com).28,29 Recovered cats should be kept indoors and tick-free to prevent them from serving as a reservoir for infection. Although reinfection has previously been deemed unlikely, a second clinical disease episode was recently documented in a cat 7 years after the first illness.20 Although candidate targets for vaccination have been identified, vaccination has thus far been ineffective.3,30


1. Blouin EF, Kocan AA, Kocan KM, Hair J. Evidence of a limited schizogonous cycle for Cytauxzoon felis in bobcats following exposure to infected ticks. J Wildl Dis 1987;23(3):499-501.

2. Reichard MV, Edwards AC, Meinkoth JH, et al. Confirmation of Amblyomma americanum (Acari: Ixodidae) as a vector for Cytauxzoon felis (Piroplasmorida: Theileriidae) to domestic cats. J Med Entomol 2010;47(5):890-896.

3. Tarigo JL, Scholl EH, Bird DM, et al. A novel candidate vaccine for cytauxzoonosis inferred from comparative apicomplexan genomics. PLoS One 2013;8(8):e71233.

4. Thomas JE, Ohmes CM, Payton ME, et al. Minimum transmission time of Cytauxzoon felis by Amblyomma americanum to domestic cats in relation to duration of infestation, and investigation of ingestion of infected ticks as a potential route of transmission. J Feline Med Surg 2018;20(2):67-72.

5. Lewis KM, Cohn LA, Birkenheuer AJ. Lack of evidence for perinatal transmission of Cytauxzoon felis in domestic cats. Vet Parasitol 2012;188(1-2):172-174.

6. Blouin EF, Kocan AA, Glenn BL, et al. Transmission of Cytauxzoon felis Kier, 1979 from bobcats, Felis rufus (Schreber), to domestic cats by Dermacentor variabilis (Say). J Wildl Dis 1984;20(3):241-242.

7. Wagner JE, Ferris DH, Kier AB, et al. Experimentally induced cytauxzoonosis-like disease in domestic cats. Vet Parasitol

8. Wagner JE. A fatal cytauxzoonosis-like disease in cats. JAVMA 1976;168(7):585-588.

9. Birkenheuer AJ, Le JA, Valenzisi AM, et al. Cytauxzoon felis infection in cats in the mid-Atlantic states: 34 cases (1998-2004). JAVMA 2006;228(4):568-571.

10. Shock BC, Murphy SM, Patton LL, et al. Distribution and prevalence of Cytauxzoon felis in bobcats (Lynx rufus), the natural reservoir, and other wild felids in thirteen states. Vet Parasitol 2011;175(3-4):325-330.

11. Meinkoth J, Kocan AA, Whitworth L, et al. Cats surviving natural infection with Cytauxzoon felis: 18 cases (1997-1998). J Vet Intern Med 2000;14(5):521-525.

12. Rizzi TE, Reichard MV, Cohn LA, et al. Prevalence of Cytauxzoon felis infection in healthy cats from enzootic areas in Arkansas, Missouri, and Oklahoma. Parasit Vectors 2015;8:13.

13. Reichard MV, Baum KA, Cadenhead SC, Snider TA. Temporal occurrence and environmental risk factors associated with cytauxzoonosis in domestic cats. Vet Parasitol 2008;152(3-4):314-320.

14. Nagamori Y, Slovak JE, Reichard MV. Prevalence of Cytauxzoon felis infection in healthy free-roaming cats in north-central Oklahoma and central Iowa. JFMS Open Rep 2016;2(1).

15. Jacobs CH. Prevalence of Cytauxzoon felis in feral cats in Russellville, Arkansas. J Arkansas Acad Sci 2018;72(21):123-128.

16. Cohn LA, Birkenheuer AJ, Brunker JD, et al. Efficacy of atovaquone and azithromycin or imidocarb dipropionate in cats with acute cytauxzoonosis. J Vet Intern Med 2011;25(1):55-60.

17. Hoover JP, Walker DB, Hedges JD. Cytauxzoonosis in cats: eight cases (1985-1992). JAVMA 1994;205(3):455-460.

18. Conner BJ, Hanel RM, Brooks MB, et al. Coagulation abnormalities in 5 cats with naturally occurring cytauxzoonosis. J Vet Emerg Crit Care 2015;254:538-545.

19. Lewis KM, Cohn LA, Marr H, Birkenheuer AJ. Diminazene diaceturate at 3 mg/kg does not eliminate parasitemia in cats with chronic Cytauxzoon felis infection. J Vet Intern Med 2012;26(3):783 (abstract).

20. Cohn LA, Shaw D, Shoemake C, Birkenheuer AJ. Second illness due to subsequent Cytauxzoon felis infection in a domestic cat. JFMS Open Rep 2020;6(1).

21. Kier AB, Wagner JE, Kinden DA. The pathology of experimental cytauxzoonosis. J Comp Path 1987;97(4):415-432.

22. Birkenheuer AJ, Marr H, Alleman AR, et al. Development and evaluation of a PCR assay for the detection of Cytauxzoon felis DNA in feline blood samples. Vet Parasitol 2006;137(1-2):144-149.

23. Reichard MV, Meinkoth JH, Edwards AC, et al. Transmission of Cytauxzoon felis to a domestic cat by Amblyomma americanum.
Vet Parasitol 2009;161(1-2):110-115.

24. Haber MD, Tucker MD, Marr HS, et al. The detection of Cytauxzoon felis in apparently healthy free-roaming cats in the USA. Vet Parasitol 2007;146(3-4):316-320.

25. Schreeg ME, Marr HS, Tarigo JL, et al. Rapid high-resolution melt analysis of Cytauxzoon felis cytochrome b to aid in the prognosis of cytauxzoonosis. J Clin Microbiol 2015;53(8):2517-2524.

26. Cohn LA, Birkenheuer AJ, Ratcliff E. Comparison of two drug protocols for clearance of Cytauxzoon felis infections. J Vet Intern Med 2008;22(3):704 (abstract).

27. Lewis KM, Cohn LA, Marr H, Birkenheuer AJB, eds. High dose diminazene diaceturate does not eliminate parasitemia in cats with chronic Cytauxzoon felis infection. ACVIM Forum; 2012 May 30–Jun 2; New Orleans, LA.

28. Reichard MV, Thomas JE, Arther RG, et al. Efficacy of an imidacloprid 10 % / flumethrin 4.5 % collar (Seresto®, Bayer) for preventing the transmission of Cytauxzoon felis to domestic cats by Amblyomma americanum. Parasitol Res 2013;112 Suppl 1:11-20.

29. Reichard MV, Rugg JJ, Thomas JE, et al. Efficacy of a topical formulation of selamectin plus sarolaner against induced infestations of Amblyomma americanum on cats and prevention of Cytauxzoon felis transmission. Vet Parasitol 2019;270 Suppl 1:S31-S37.

30. Schreeg ME, Marr HS, Tarigo JL, et al. Identification of Cytauxzoon felis antigens via protein microarray and assessment of expression library immunization against cytauxzoonosis. Clin Proteomics 2018;15:44.